AMLX
Amylyx Pharmaceuticals Inc
29.50$
-2.2%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | -103.6% | – | – | – | – | – | – | – | – | – | – | |
| – | -0.3% | +4.7% | -34.0% | +6.3% | -27.6% | -2.5% | -9.6% | -14.9% | -10.0% | -9.3% | -56.1% | – | |
| – | -6.3% | +4.1% | -3.6% | -28.9% | -0.9% | +1.4% | +7.6% | -3.7% | -9.8% | -4.2% | +35.9% | – | |
| – | – | -89.5% | -5,401.8% | – | – | – | – | -119.4% | – | -5,817.4% | – | – | |
| – | -0.3% | -81.2% | +32.8% | -78.7% | +5.3% | -45.0% | +54.5% | +41.2% | +258.3% | -100.0% | – | – | |
| – | – | -96.1% | -3,636.1% | – | +67.4% | -167.2% | – | -77.2% | +462.8% | +23.1% | -513.1% | – | |
| – | +23.2% | +1,023.9% | -98.5% | – | – | – | – | – | – | – | – | – | |
| – | -74.1% | -43.0% | -79.4% | +196.3% | +37.5% | +59,592.7% | -100.0% | – | -100.1% | – | -54.0% | – | |
| – | – | -99.0% | -27,323.1% | – | – | -417.1% | – | – | -99.1% | +68.5% | -7,335.8% | – | |
| – | – | -104.2% | – | – | – | – | – | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.